The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs
Open accessAbstract
Combination therapy with protease (PR) and reverse transcriptase (RT) inhibitors can efficiently suppress human immunodeficiency virus (HIV) replication, but the emergence of drug-resistant variants correlates strongly with therapeutic failure. Here we describe a new method for high-throughput analysis of clinical samples that permits the simultaneous detection of HIV type 1 (HIV-1) phenotypic resistance to both RT and PR inhibitors by means of recombinant virus assay technology. HIV-1 RNA is extracted from plasma samples, and a 2.2-kb fragment containing the entire HIV-1 PR- and RT-coding sequence is amplified by nested reverse transcription-PCR. The pool of PR-RT-coding sequences is then cotransfected into CD4 + T lymphocytes (MT4) with the pGEMT3ΔPRT plasmid from which most of the PR (codons 10 to 99) and RT (codons 1 to 482) sequences are deleted. Homologous recombination leads to the generation of chimeric viruses containing PR- and RT-coding sequences derived from HIV-1 RNA in plasma. The susceptibilities of the chimeric viruses to all currently available RT and/or PR inhibitors is determined by an MT4 cell–3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide-based cell viability assay in an automated system that allows high sample throughput. The profile of resistance to all RT and PR inhibitors is displayed graphically in a single PR-RT-Antivirogram. This assay system facilitates the rapid large-scale phenotypic resistance determinations for all RT and PR inhibitors in one standardized assay.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., Leonard, J. M., & Markowitz, M. (1995) · Nature · doi:10.1038/373123a0 · Cited by 4,267
HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time
Perelson, A. S., Neumann, A. U., Markowitz, M., Leonard, J. M., & Ho, D. D. (1996) · Science · doi:10.1126/science.271.5255.1582 · Cited by 3,531
Viral dynamics in human immunodeficiency virus type 1 infection
Wei, X., Ghosh, S. K., Taylor, M. E., Johnson, V. A., Emini, E. A., Deutsch, P., Lifson, J. D., Bonhoeffer, S., Nowak, M. A., Hahn, B. H., et al. (1995) · Nature · doi:10.1038/373117a0 · Cited by 3,260
Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma
Mellors, J. W., Rinaldo, C. R., Gupta, P., White, R. M., Todd, J. A., & Kingsley, L. A. (1996) · Science · doi:10.1126/science.272.5265.1167 · Cited by 2,660
Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds
Pauwels, R., Balzarini, J., Baba, M., Snoeck, R., Schols, D., Herdewijn, P., Desmyter, J., & De Clercq, E. (1988) · Journal of Virological Methods · doi:10.1016/0166-0934(88)90134-6 · Cited by 1,642
Self-citationHIV with Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged Therapy
Larder, B. A., Darby, G., & Richman, D. D. (1989) · Science · doi:10.1126/science.2467383 · Cited by 1,559
Self-citationMultiple Mutations in HIV-1 Reverse Transcriptase Confer High-Level Resistance to Zidovudine (AZT)
Larder, B. A., & Kemp, S. D. (1989) · Science · doi:10.1126/science.2479983 · Cited by 1,163
Self-citationIn vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
Condra, J. H., Schleif, W. A., Blahy, O. M., Gabryelski, L. J., Graham, D. J., Quintero, J., Rhodes, A., Robbins, H. L., Roth, E., Shivaprakash, M., et al. (1995) · Nature · doi:10.1038/374569a0 · Cited by 974
Direct Observation of Vortex Dynamics in Superconducting Films with Regular Arrays of Defects
Harada, K., Kamimura, O., Kasai, H., Matsuda, T., Tonomura, A., & Moshchalkov, V. V. (1996) · Science · doi:10.1126/science.274.5290.1167 · Cited by 778
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
Molla, A., Korneyeva, M., Gao, Q., Vasavanonda, S., Schipper, P. J., Mo, H.-M., Markowitz, M., Chernyavskiy, T., Niu, P., Lyons, N., et al. (1996) · Nature Medicine · doi:10.1038/nm0796-760 · Cited by 762
Carpenter, C. C. J. (1997) · JAMA · doi:10.1001/jama.1997.03540480062040 · Cited by 725
Resistance to ddI and Sensitivity to AZT Induced by a Mutation in HIV-1 Reverse Transcriptase
St. Clair, M. H., Martin, J. L., Tudor-Williams, G., Bach, M. C., Vavro, C. L., King, D. M., Kellam, P., Kemp, S. D., & Larder, B. A. (1991) · Science · doi:10.1126/science.1716788 · Cited by 679
Self-citationPotential Mechanism for Sustained Antiretroviral Efficacy of AZT-3TC Combination Therapy
Larder, B. A., Kemp, S. D., & Harrigan, P. R. (1995) · Science · doi:10.1126/science.7542804 · Cited by 623
Self-citationTisdale, M., Kemp, S. D., Parry, N. R., & Larder, B. A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.12.5653 · Cited by 603
Self-citationNevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy
Richman, D. D., Havlir, D., Corbeil, J., Looney, D., Ignacio, C., Spector, S. A., Sullivan, J., Cheeseman, S., Barringer, K., & Pauletti, D. (1994) · Journal of Virology · doi:10.1128/jvi.68.3.1660-1666.1994 · Cited by 576
Kempf, D. J., Marsh, K. C., Denissen, J. F., McDonald, E., Vasavanonda, S., Flentge, C. A., Green, B. E., Fino, L., Park, C. H., & Kong, X. P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.7.2484 · Cited by 560
Mulder, J., McKinney, N., Christopherson, C., Sninsky, J., Greenfield, L., & Kwok, S. (1994) · Journal of Clinical Microbiology · doi:10.1128/jcm.32.2.292-300.1994 · Cited by 558
Carpenter, C. C. J. (1996) · JAMA · doi:10.1001/jama.276.2.146 · Cited by 541
Antiretroviral Therapy for HIV Infection: A Knowledge-Based Approach to Drug Selection and Use
Moyle, G. J., Gazzard, B. G., Cooper, D. A., & Gatell, J. (1998) · Drugs · doi:10.2165/00003495-199855030-00005 · Cited by 536
HIV viral load markers in clinical practice
Saag, M. S., Holodniy, M., Kuritzkes, D. R., O'Brien, W. A., Coombs, R., Poscher, M. E., Jacobsen, D. M., Shaw, G. M., Richman, D. D., & Volberding, P. A. (1996) · Nature Medicine · doi:10.1038/nm0696-625 · Cited by 524
L-735,524: The Design of a Potent and Orally Bioavailable HIV Protease Inhibitor
Dorsey, B. D., Levin, R. B., McDaniel, S. L., Vacca, J. P., Guare, J. P., Darke, P. L., Zugay, J. A., Emini, E. A., & Schleif, W. A. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00047a001 · Cited by 412
Condra, J. H., Holder, D. J., Schleif, W. A., Blahy, O. M., Danovich, R. M., Gabryelski, L. J., Graham, D. J., Laird, D., Quintero, J. C., Rhodes, A., et al. (1996) · Journal of Virology · doi:10.1128/jvi.70.12.8270-8276.1996 · Cited by 405
Implications of the late Palaeozoic oxygen pulse for physiology and evolution
Graham, J. B., Aguilar, N. M., Dudley, R., & Gans, C. (1995) · Nature · doi:10.1038/375117a0 · Cited by 325
Japour, A. J., Mayers, D. L., Johnson, V. A., Kuritzkes, D. R., Beckett, L. A., Arduino, J. M., Lane, J., Black, R. J., Reichelderfer, P. S., & D'Aquila, R. T. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.5.1095 · Cited by 294
Mutations in Retroviral Genes Associated with Drug Resistance
Mellors, J. W., Schinazi, R. F., & Larder, B. A. (1996) · Cited by 285
Self-citationIversen, A. K., Shafer, R. W., Wehrly, K., Winters, M. A., Mullins, J. I., Chesebro, B., & Merigan, T. C. (1996) · Journal of Virology · doi:10.1128/jvi.70.2.1086-1090.1996 · Cited by 245
Stuyver, L., Wyseur, A., Rombout, A., Louwagie, J., Scarcez, T., Verhofstede, C., Rimland, D., Schinazi, R. F., & Rossau, R. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.2.284 · Cited by 234
van Gemen, B., van Beuningen, R., Nabbe, A., van Strijp, D., Jurriaans, S., Lens, P., & Kievits, T. (1994) · Journal of Virological Methods · doi:10.1016/0166-0934(94)90040-x · Cited by 211
Kellam, P., & Larder, B. A. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.1.23 · Cited by 199
Self-citationQuantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing
Larder, B. A., Kohli, A., Kellam, P., Kemp, S. D., Kronick, M., & Henfrey, R. D. (1993) · Nature · doi:10.1038/365671a0 · Cited by 198
Self-citationAntiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase
Craig, J. C., Duncan, I. B., Hockley, D., Grief, C., Roberts, N. A., & Mills, J. S. (1991) · Antiviral Research · doi:10.1016/0166-3542(91)90045-s · Cited by 189
Tisdale, M., Myers, R. E., Maschera, B., Parry, N. R., Oliver, N. M., & Blair, E. D. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.8.1704 · Cited by 180
Dewar, R. L., Highbarger, H. C., Sarmiento, M. D., Todd, J. A., Vasudevachari, M. B., Davey, R. T., Kovacs, J. A., Salzman, N. P., Lane, H. C., & Urdea, M. S. (1994) · Journal of Infectious Diseases · doi:10.1093/infdis/170.5.1172 · Cited by 166
Kusumi, K., Conway, B. R., Cunningham, S., et al. (1992) · Journal of Virology · doi:10.1128/jvi.66.2.875-885.1992 · Cited by 147
Sardana, V. V., Emini, E. A., Gotlib, L., Graham, D. J., Lineberger, D. W., Long, W. J., Schlabach, A. J., Wolfgang, J., & Condra, J. H. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)37074-7 · Cited by 112
Resistance of HIV Type 1 to Proteinase Inhibitor Ro 31-8959
Eberle, J., BECHOWSKY, B., Rose, D., Hauser, U., von der Helm, K., Gürtler, L. G., & Nitschko, H. (1995) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1995.11.671 · Cited by 76
Cited by
Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database
Shafer, R. W., Stevenson, D., & Chan, B. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.348 · Cited by 907
Hirsch, M. S., Günthard, H. F., Schapiro, J. M., Brun‐Vézinet, F., Clotet, B., Hammer, S. M., Johnson, V. A., Kuritzkes, D. R., Mellors, J. W., Pillay, D., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/589297 · Cited by 573
Hirsch, M. S., Conway, B., D'Aquila, R. T., Johnson, V. A., Brun-Vézinet, F., Clotet, B., Demeter, L. M., Hammer, S. M., Jacobsen, D. M., Kuritzkes, D. R., et al. (1998) · JAMA · doi:10.1001/jama.279.24.1984 · Cited by 563
HIV-1 Drug Resistance in Newly Infected Individuals
Boden, D. (1999) · JAMA · doi:10.1001/jama.282.12.1135 · Cited by 466
DeGruttola, V., Dix, L., D'Aquila, R., Holder, D., Phillips, A., Ait-Khaled, M., Baxter, J., Clevenbergh, P., Hammer, S., Harrigan, R., et al. (2000) · Antiviral Therapy · doi:10.1177/135965350000500112 · Cited by 326
Self-citation
Metadata
- Authors
- Hertogs, K., de Béthune, M.-P., Miller, V., Ivens, T., Schel, P., Van Cauwenberge, A., Van den Eynde, C., van Gerwen, V., Azijn, H., van Houtte, M., Peeters, F., Staszewski, S., Conant, M., Bloor, S., Kemp, S., Larder, B., & Pauwels, R.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1998-02
- Volume
- 42
- Issue
- 2
- Pages
- 269-276
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2134713579
- Cited by
- 389
- References
- 36
- FWCI
- 28.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.